胰腺癌新药丸或成突破性疗法

Compared with traditional chemotherapy, a pill called daraxonrasib nearly doubled the survival time of people with advanced pancreatic cancer, scientists reported to multiple rounds of applause at the annual American Society of Clinical Oncology meeting in Chicago. Half of patients on the new drug lived 13 months or longer after treatment. In comparison, the median survival time was less than seven months for those on chemo. An extra six months of life might not sound like much, but “it’s a drastic improvement,” says oncologist Andrew Coveler of the Fred Hutchinson Cancer Center in Seattle. Survival time for people with advanced cancer that’s spread beyond the pancreas is often less than a year. …